- Home
- BILI vs SNN Comparison
BILI vs SNN Comparison
Compare BILI & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BILI | SNN |
|---|---|---|
| Founded | 2009 | 1856 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 14.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BILI | SNN |
|---|---|---|
| Price | $22.33 | $31.68 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | $31.15 | ★ $36.25 |
| AVG Volume (30 Days) | ★ 2.6M | 790.5K |
| Earning Date | 03-05-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.33% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.87 | $7.19 |
| Revenue Next Year | $9.51 | $5.36 |
| P/E Ratio | $122.37 | ★ $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.47 | $23.91 |
| 52 Week High | $36.40 | $38.79 |
Technical Indicators
Market Signals| Indicator | BILI | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 31.07 | 32.93 |
| Support Level | $21.95 | $29.27 |
| Resistance Level | $25.67 | $33.89 |
| Average True Range (ATR) | 0.74 | 0.53 |
| MACD | -0.17 | -0.15 |
| Stochastic Oscillator | 3.07 | 0.90 |
Price Performance
Historical ComparisonAbout BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing site. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, catering primarily to Gen Z users. Over time, the platform has broadened its content offerings to include a wider range of interests, successfully attracting a more diverse audience beyond the Gen Z demographic.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.